Recruiting
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
ClinicalTrials.gov IDNCT06259162
PhaseNA
Enrollment128
SponsorSamsung Medical Center
AgeNo minimum reported
SexFEMALE
Conditions studied
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
About this study
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Interventions
- Procedure: LAG-3 expression / immune checkpoint protein expression — Evaluate the tissue and blood before and after chemotherapy
Primary outcomes
- LAG-3 expression/immune checkpoint preotein expression (Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery)
Eligibility information
Inclusion Criteria:
* Planned neoadjuvant chemotherapy
* Triple negative breast cancer
Exclusion Criteria:
* HER2-positive breast cancer
* Hormone receptor positive breast cancer
Study locations
- Ji-Yeon Kim, Seoul, 06351 South Korea
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.